295 related articles for article (PubMed ID: 12514429)
1. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
2. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
[TBL] [Abstract][Full Text] [Related]
3. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
4. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
[TBL] [Abstract][Full Text] [Related]
5. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.
Mukherjee P; Tinder TL; Basu GD; Pathangey LB; Chen L; Gendler SJ
Breast Dis; 2004; 20():53-63. PubMed ID: 15687707
[TBL] [Abstract][Full Text] [Related]
8. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.
Heukamp LC; van Hall T; Ossendorp F; Burchell JM; Melief CJ; Taylor-Papadimitriou J; Offringa R
J Immunother; 2002; 25(1):46-56. PubMed ID: 11926165
[TBL] [Abstract][Full Text] [Related]
9. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
[TBL] [Abstract][Full Text] [Related]
10. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
11. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
12. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
13. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines.
Acres B; Apostolopoulos V; Balloul JM; Wreschner D; Xing PX; Ali-Hadji D; Bizouarne N; Kieny MP; McKenzie IF
Cancer Immunol Immunother; 2000 Jan; 48(10):588-94. PubMed ID: 10630311
[TBL] [Abstract][Full Text] [Related]
14. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
[TBL] [Abstract][Full Text] [Related]
17. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo.
Mukherjee P; Ginardi AR; Tinder TL; Sterner CJ; Gendler SJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):848s-855s. PubMed ID: 11300482
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model.
McConnell EJ; Pathangey LB; Madsen CS; Gendler SJ; Mukherjee P
J Surg Res; 2002 Oct; 107(2):196-202. PubMed ID: 12429175
[TBL] [Abstract][Full Text] [Related]
19. Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.
Curry JM; Besmer DM; Erick TK; Steuerwald N; Das Roy L; Grover P; Rao S; Nath S; Ferrier JW; Reid RW; Mukherjee P
PLoS One; 2019; 14(11):e0224309. PubMed ID: 31693710
[TBL] [Abstract][Full Text] [Related]
20. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]